Nicotinamide riboside: A new promising therapy for type-I cardio-renal syndrome management - 18/05/21
Résumé |
Introduction |
Epidemiological evidence correlates acute myocardial infarction (MI) with acute kidney injury (AKI), otherwise known as type-I cardio-renal syndrome (CRS). Multiple studies reported a decrease in tissue nicotinamide adenine dinucleotide (NAD) levels in myocardium in the setting of heart diseases and in the kidneys following AKI. The correlation between myocardial and renal NAD+ homeostasis in the context of type-I CRS, however, is yet to be determined as well as the opportunity to boost NAD synthesis in this pathological context.
Objective |
We aim at evaluating the cardiac and renal protective effects of nicotinamide riboside (NR) supplementation, a precursor of NAD used by salvage enzymes renal NMRK1 and cardiac NMRK2, in a mouse model of large MI.
Methods |
C57BL6/J male mice were divided into four groups: Sham+Vehicle, Sham+NR, MI+Vehicle, and MI+NR. NR was administered daily by intraperitoneal injection for either 4 or 7days (D) post-MI. Echocardiography was performed and kidney structural, molecular, and functional levels were evaluated.
Results |
Myocardial NAD levels were reduced at D4 and D7 post-MI when compared to the SHAM groups while they were maintained in MI+NR group. Renal NAD levels remained unchanged at D4 and D7 post-MI, whereas, NR treatment doubled NAD levels compared to the SHAM groups. Cardiac functional analysis revealed a comparable decrease in ejection fraction and cardiac output post-MI with or without NR treatment. Urine output decreased in mice at D4 and D7 post-MI but was maintained in NR treated mice. Kidney morphological alterations characterized by proximal tubule dilatation, fibrosis, and cell death markedly increased post-MI (D4 and D7), whereas NR treatment protected against these alterations.
Conclusion |
NR supplementation appears as a promising therapy for type I CRS. Further experiments are warranted to decipher the molecular pathways involved in the observed protection.
Le texte complet de cet article est disponible en PDF.Plan
Vol 13 - N° 2
P. 196-197 - mai 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.